EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study

Javier Mataix Díaz iD, Sergio Santos Alarcón, Isabel Belinchón Romero, Luca Schneller-Pavelescu Apetrei iD, Laura García Fernández iD, Francisco Javier Melgosa Ramos iD, Fernando Toledo Alberola, María Asunción Ballester Martínez, Adrián Ballano Ruiz iD, Ofelia Baniandrés Rodríguez iD, Ricardo Ruiz-Villaverde iD, María Castellanos González und 5 weitere

Australasian Journal of Dermatology · 2026-02 · 67 (1)

DOI: 10.1111/ajd.70012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 05.12.2025. Verfasst von Javier Mataix Díaz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Marina Baixa de Villajoyosa, Alicante, Spain. Hauptthemen laut MEDLINE: Psoriasis, Neoplasms, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate‐to‐severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 ± 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment‐related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisNeoplasmsAntibodies, MonoclonalDermatologic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedSpainAdultAgedTreatment OutcomeSeverity of Illness Index

Substanzen

risankizumabAntibodies, MonoclonalDermatologic Agents

Autor:innen und Institutionen

  • Hospital Marina Baixa de Villajoyosa, Alicante, Spain.
  • Hospital Virgen de los Lirios, Alcoy, Spain.
  • Hospital General Universitario Dr. Balmis, ISABIAL, Alicante, Spain.
  • Hospital Vega Baja, Orihuela, Spain.
  • Hospital Universitario de San Juan de Alicante, San Juan de Alicante, Spain.
  • Hospital Lluís Alcanyís, Xàtiva, Spain.

ORCID-Profile: Javier Mataix Díaz, Luca Schneller-Pavelescu Apetrei, Laura García Fernández, Francisco Javier Melgosa Ramos, Adrián Ballano Ruiz, Ofelia Baniandrés Rodríguez, Ricardo Ruiz-Villaverde, Jorge Magdaleno Tapial

Zitieren

APA

Díaz, J. M., Alarcón, S. S., Romero, I. B., Apetrei, L. S., Fernández, L. G., Ramos, F. J. M., Alberola, F. T., Martínez, M. A. B., Ruiz, A. B., Rodríguez, O. B., Ruiz-Villaverde, R., González, M. C., Farrés, M. F., Puchades, A. M., Tapial, J. M., Rull, E. V., & Montalvo, S. M. (2026). Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study. Australasian Journal of Dermatology, 67(1). https://doi.org/10.1111/ajd.70012

Vancouver

Díaz JM, Alarcón SS, Romero IB, Apetrei LS, Fernández LG, Ramos FJM, et al. Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study. Australasian Journal of Dermatology. 2026;67(1). doi:10.1111/ajd.70012

BibTeX
@article{Daz2026,
  author = {Díaz, Javier Mataix and Alarcón, Sergio Santos and Romero, Isabel Belinchón and Apetrei, Luca Schneller-Pavelescu and Fernández, Laura García and Ramos, Francisco Javier Melgosa and Alberola, Fernando Toledo and Martínez, María Asunción Ballester and Ruiz, Adrián Ballano and Rodríguez, Ofelia Baniandrés and Ruiz-Villaverde, Ricardo and González, María Castellanos and Farrés, Marta Ferrán and Puchades, Almudena Mateu and Tapial, Jorge Magdaleno and Rull, Eva Villarrasa and Montalvo, Susana Medina},
  title = {Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  volume = {67},
  number = {1},
  doi = {10.1111/ajd.70012}
}
Kostenlos starten →